Post-Treatment Surveillance in Breast Cancer: Bringing CER to the Alliance

Sponsor

University of Wisconsin, Madison (Other)

Overall Status

Completed

CT.gov ID

NCT02171078

Collaborator

Patient-Centered Outcomes Research Institute (Other), American College of Surgeons (Other), Alliance for Clinical Trials in Oncology (Other), Harvard University (Other), Dana-Farber Cancer Institute (Other), M.D. Anderson Cancer Center (Other), University of North Carolina, Chapel Hill (Other)

34,359

Enrollment

Location

Duration (Months)

817.7

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Nearly three million living women have survived breast cancer. Physicians rely on clinical practice guidelines to make decisions on follow-up care. Among other things, the goal is to monitor for recurrence or side effects of treatment among survivors. It is unclear whether these guidelines represent the best approach for any given patient as they do not account for differences in disease or patient preferences and may not consider recent advances in imaging and treatment options. We seek to develop a new approach to surveillance following breast cancer treatment which will be more patient-centered and effective than the existing one-size-fits-all approach and will consider individual risk factors.

Condition or Disease	Intervention/Treatment	Phase
Breast Neoplasms

Detailed Description

Our project involves three primary goals:

Use existing data from clinical trials sponsored by one of the leading cancer cooperative groups to evaluate how risk of recurrence and side effects of treatment vary based on patient and cancer characteristics.
Use existing data to evaluate the effectiveness of the latest imaging technology for improving survival in patients previously treated for breast cancer.
Engage cancer survivors, providers, and health outcomes researchers in the development of an improved patient-centered approach to guide post-treatment care, as well as identification of the highest priority strategies for prospective randomized trials.

Methods Our methods have been developed based on input from patients and other stakeholders who identified the need for a large-scale observational study. The goal is to produce timely results, and guide the development of an improved approach to surveillance that recognizes individual patient risk factors and allows for design of future prospective studies. This study analyzes recurrence data and treatment side effects on over 22,000 patients involved in past clinical trials on breast cancer care. The project also involves the analysis of existing data (n=15,000 patients) from a national cancer registry (National Cancer Database) to evaluate whether new imaging technology, beyond mammography, are able to detect recurrence earlier and improve survival. Finally, we will engage cancer survivors, health care providers, and researchers to develop new guidance for the care and monitoring of breast cancer survivors, and to guide and prioritize future prospective trials.

Study Design

Study Type:

Observational

Actual Enrollment :

34359 participants

Observational Model:

Other

Time Perspective:

Other

Official Title:

Post-Treatment Surveillance in Breast Cancer: Bringing CER to the Alliance

Study Start Date :

Jun 1, 2014

Actual Primary Completion Date :

Dec 1, 2017

Actual Study Completion Date :

Dec 1, 2017

Arms and Interventions

Arm	Intervention/Treatment
Alliance for Clinical Trials Database Use existing data from clinical trials sponsored by one of the leading cancer cooperative groups to evaluate how risk of recurrence and side effects of treatment vary based on patient and cancer characteristics.
National Cancer Database Use existing data to evaluate the effectiveness of the latest imaging technology for detecting recurrence and improving survival in patients previously treated for breast cancer.
Stakeholder Engagement Engage cancer survivors, providers, and health outcomes researchers in the development of an improved patient-centered approach to guide post-treatment care, as well as identification of the highest priority strategies for prospective randomized trials.

Outcome Measures

Primary Outcome Measures

Time to Recurrence [5 Years from Diagnosis]
Data elements include the date and site of recurrence, type of recurrence (e.g., local/regional or distant recurrence), and progression.
Time to Toxicity/Side Effects of Treatment [Within relevant timeframe of legacy clinical trial. Most trials include 2-year follow-up]
Legacy clinical trials contain detailed data on treatment toxicity and complications. Most trials include 2-year follow-up to determine the prevalence and time to presentation for each of the following toxicities: lymphedema, cardiotoxicity, and pneumonitis Safety Issue?: No